Researchers to Decode Antarctic Ice Metagenome with the 454 Sequencing System, to Explore the Effects of Climate Change
Previously performed projects at the Alfred Wegener Institute and University of East Anglia have completed the genome sequence of a sea ice alga and a bacterium. Moreover they sequenced transcriptomes of sea ice species and communities - the goal of these studies was to decode the active genes contributing to the genetic adaptation of these species to the extreme Antarctic environment. As part of their new metagenomic study, the researchers plan to analyze the complete set of organisms found in the arctic ice and hope to find genes which are "turned off" within the organisms.
"In order to gain knowledge about the potentials which slumber in the genome, we will sequence both active and inactive genes," explained Valentin. "If environmental factors like temperature, carbon dioxide concentration, or light intensity change in the future, it is important to know which genomic potentials polar biocoenosis have to resist the climatic change."
During the past several decades, climate change has had a tremendous impact on Arctic ecosystems, including sea ice, forests and tundra. As Arctic temperatures rise, the plant, animal, and bacterial species which inhabit the region are forced to either adapt to the changes in the environmental or perish.
"We are pleased to see the technology of 454 Sequencing being applied to the important field of polar biocoenosis research," said Chris McLeod, President and CEO of 454 Life Sciences, a Roche company. "Their results will help to understand better the impacts of global warming in that region."
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative 454 Sequencing System for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the 454 Sequencing System are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the 454 Sequencing System has enabled hundreds of peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more.
About Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.